Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cause of cancer mortality in the world. Some progress has been made in the therapy of HNSCC, however treatment remains unsatisfactory. Recent studies have shown that different types of long non-coding RNAs (lncRNAs) are dysregulated in HNSCC and correlate with tumor progression, lymph node metastasis, clinical stage and poor...

High-risk human papillomaviruses (HPVs) contribute to cervical and other anogenital cancers, and they are also linked etiologically to a subset of head and neck squamous cell carcinomas (HNSCC). We previously established a model for HPV-associated HNSCC in which we treated transgenic mice expressing the papillomaviral oncoproteins with the chemical carcinogen 4-nitroquinoline-1-oxide (4-NQO). W...

Worldwide, more than 550, 000 new cases of head and neck squamous cell carcinoma (HNSCC) are estimated to occur annually, making it the sixth most common human ma‐ lignancy. Since their discovery in 2007, cancer stem cells (CSCs) in HNSCC have garnered increased interest secondary to their properties of tumorigenicity, differentiation, prolif‐ eration, and self-renewal. CSCs are intrinsically m...

BACKGROUND The aim of this study was to determine whether haptoglobin (Hp) genotypes are associated with prognosis in patients with squamous cell carcinoma of the head and neck (HNSCC). METHODS We studied patients with HNSCC without distant metastasis at diagnosis. The Hp genotype of each patient was determined and the prognostic significance of the Hp genotype was further analyzed. Pearson's...

BACKGROUND Monocyte chemotactic protein-1 (MCP-1) recruits monocytes and macrophages to inflammation sites, and inflammatory infiltration correlates with the progression of head and neck squamous cell carcinoma (HNSCC). This study aims to determine whether MCP-1 expression is related to HNSCC malignancy and patient survival. We also investigated the relationship between MCP-1 expression and the...

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. Mutations of TP53 may reach 70% - 85% in HNSCC patients without human papillomavirus (HPV) infection. Recurrence rate remains particularly high for HNSCC patients with mutations in the TP53 gene although patients are responsive to surgery, irradiation, and chemotherapy early in the treatment. p53-Reactivati...

PURPOSE In other cancer types, HPV infection has been reported to coincide with overexpression of HER2 (ERBB2) and HER3 (ERBB3); however, the association between HER2 or HER3 expression and dimer formation in HNSCC has not been reported. Overexpression of HER2 and HER3 may contribute to resistance to EGFR inhibitors, including cetuximab, although the contribution of HPV in modulating cetuximab ...

BACKGROUND Metabolomics represents a promising approach for discovering novel targets and biomarkers in head and neck squamous cell carcinoma (HNSCC). Here we used metabolomics to identify oral metabolites associated with HNSCC. METHODS Tumor and adjacent normal tissue from surgical resections and presurgical oral washes as well as oral washes were collected from healthy participants. Metabol...

BACKGROUND Metastasis to regional lymph nodes via lymphatic vessels plays a key role in cancer progression. Tumor lymphangiogenesis is known to promote lymphatic metastasis, and vascular endothelial growth factor C (VEGF-C) is a critical activator of tumor lymphangiogenesis during the process of metastasis. We previously identified periostin as an invasion- and angiogenesis-promoting factor in ...

The incidence of squamous cell carcinoma of the head and neck (HNSCC) reaches as high as 16.5 cases per 100,000 individuals in the United States (1). Earlystage lesions have a favorable prognosis when treated surgically, but approximately two-thirds of HNSCC are diagnosed at an advanced locoregional stage (2). Chemoradiation is the backbone of treatment for the majority of advanced tumors, and ...